Tadact 20 contains tadalafil as its active ingredient, and it belongs to a class of medications known as phosphodiesterase type 5 (PDE5) inhibitors. Tadalafil is commonly used to treat erectile dysfunction (ED) in men. The mechanism of action of Tadact 20 in treating erectile dysfunction involves its effects on the cyclic guanosine monophosphate (cGMP) pathway.

Here is a simplified explanation of the mechanism of action:

Release of Nitric Oxide (NO): Sexual stimulation leads to the release of nitric oxide (NO) in the erectile tissue of the penis. Nitric oxide activates an enzyme called guanylate cyclase.

Increase in cGMP Levels: Guanylate cyclase converts guanosine triphosphate (GTP) into cyclic guanosine monophosphate (cGMP). cGMP serves as a second messenger in the signaling cascade that leads to smooth muscle relaxation in the penile arteries and corpus cavernosum (erectile tissue).

Relaxation of Smooth Muscle: Increased levels of cGMP result in the relaxation of smooth muscle cells within the blood vessels of the penis. This relaxation allows increased blood flow into the penile arteries, leading to an erection.

PDE5 Inhibition by Tadalafil: Phosphodiesterase type 5 (PDE5) is an enzyme that breaks down cGMP, limiting its duration of action. Tadalafil, the active ingredient in Tadact 20, inhibits PDE5, preventing the breakdown of cGMP.

Prolonged Vasodilation: By inhibiting PDE5, tadalafil prolongs the effects of cGMP, maintaining smooth muscle relaxation and vasodilation in the penile blood vessels. This allows for improved blood flow and sustained erectile function.

It's important to note that sexual stimulation is necessary for the effectiveness of Tadact 20. The medication does not cause an automatic erection but rather enhances the natural response to sexual stimulation.